Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

LEAVE THIS BLANK

Payment Information We accept all major credit cards

By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.
RETURN TO HOME
$599
GLP-1RA, SGLT2i

Sanofi Terminates Partnership with Lexicon for Sotagliflozin Development

Here is a brief preview of this blast: In a press release announcing topline results from three Ph3 sotagliflozin T2DM trials, Sanofi disclosed that it is "terminating the collaboration to develop, manufacture, and commercialize Zynquista in all ongoing global type 1 and type 2 diabetes programs." Following Sanofi's press release, Lexicon issued its own statement declaring Sanofi's "notice invalid and Sanofi to be in breach of contract." Below, FENIX provides initial thoughts and insights about the partnership termination including readthrough to AZ and BI/Lilly.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.